Trials / Completed
CompletedNCT04704713
Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)
A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Clinuvel Pharmaceuticals Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was to evaluate the safety and efficacy of afamelanotide in patients suffering from polymorphic light eruption (PLE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afamelanotide | |
| DRUG | Placebo |
Timeline
- Start date
- 2010-05-05
- Primary completion
- 2010-12-09
- First posted
- 2021-01-12
- Last updated
- 2021-03-19
- Results posted
- 2021-03-19
Source: ClinicalTrials.gov record NCT04704713. Inclusion in this directory is not an endorsement.